Results 121 to 130 of about 182,500 (270)

IgE-mediated anaphylaxis induced by pembrolizumab

open access: yes
International audienceThe increasing use of biologics in cancer treatment is associated with an increase in drug-related hypersensitivity reactions (HSR) of varying severity.
Perotin, Jeanne-Marie   +3 more
core   +1 more source

Complete Pathologic Response to Neoadjuvant Pembrolizumab Captured on Intraoperative PET/CT: A Case Report and Exploratory Analysis

open access: yesHead &Neck, EarlyView.
ABSTRACT Background Neoadjuvant immunotherapy is an emerging treatment for patients with head and neck cancer. Given the heterogeneity of response, novel methods of intraoperative tumor and margin assessment warrant investigation. Methods A 55‐year‐old male presented with a cT3N2c supraglottic squamous cell carcinoma with a combined positive score of 5.
Joaquin Austerlitz   +7 more
wiley   +1 more source

Treatment Patterns and Survival Outcomes of Head and Neck Merkel Cell Carcinoma: An Age‐Stratified Analysis

open access: yesHead &Neck, EarlyView.
ABSTRACT Background H&N Merkel cell carcinoma (MCC) mainly affects elderly patients, yet age‐stratified treatment patterns and outcomes data are scarce. Methods We analyzed 88 consecutive H&N MCC patients (2000–2022) by age (< 75 vs. ≥ 75 years). OS was estimated by Kaplan–Meier analysis and MCC‐specific death with competing‐risks methods (cause ...
Igor Vainer   +3 more
wiley   +1 more source

Spatial comparison of molecular features associated with resistance to pembrolizumab in BCG unresponsive bladder cancer

open access: yesJournal for ImmunoTherapy of Cancer
Intravenous immune checkpoint inhibition achieves a 40% 3-month response in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ.
Joshua J Meeks   +4 more
doaj   +1 more source

Unforeseen complications of pembrolizumab in breast reconstruction post-mastectomy [PDF]

open access: yes
A 53-year-old post-menopausal Indian female presented with invasive ductal carcinoma, treated with neoadjuvant chemotherapy and pembrolizumab due to a PD-L1 combined positive score of 5.
Sohail Singh Sodhi   +4 more
core   +1 more source

Immunotherapy for Head and Neck Cutaneous Squamous Cell Carcinoma with Perineural Spread: A Systematic Review

open access: yesHead &Neck, EarlyView.
ABSTRACT Background Immunotherapy is increasingly used for head and neck cutaneous squamous cell carcinoma (cSCC) with perineural spread (PNS), though outcomes remain poorly defined. Methods A systematic review was conducted according to PRISMA and MOOSE guidelines.
Jai Paris   +4 more
wiley   +1 more source

Tolerance of Concurrent Adjuvant Radiation Therapy and Pembrolizumab for Triple Negative Breast Cancer: Real Life Experience

open access: yesAdvances in Radiation Oncology
Purpose: The current standard-of-care management of locally advanced triple negative breast cancer (TNBC) is based on neoadjuvant chemo-immunotherapy with pembrolizumab, surgery, radiation therapy (RT), and adjuvant pembrolizumab.
Thais Tison, MD   +14 more
doaj   +1 more source

Immune-related adverse events after commencing pembrolizumab therapy.

open access: yes, 2019
Immune-related adverse events after commencing pembrolizumab therapy.
Hiroyuki Kurebe (5693162)   +13 more
core   +1 more source

A multilevel perspective on MSH6‐associated Lynch syndrome: Integrating molecular, biological, and clinical insights

open access: yesInternational Journal of Cancer, EarlyView.
Abstract Lynch syndrome (LS) is the most common hereditary colorectal cancer syndrome, caused by a germline pathogenic variant in one of the mismatch repair (MMR) genes. Among these, MSH6‐associated LS represents a distinct subtype with unique molecular and clinical characteristics.
Salwa Ben Yahia   +4 more
wiley   +1 more source

A randomized, open-label, phase 3 trial of pembrolizumab plus epacadostat versus sunitinib or pazopanib as first-line treatment for metastatic renal cell carcinoma (KEYNOTE-679/ECHO-302)

open access: yesBMC Cancer
Background Immunotherapy-based combinations have emerged as standard therapies for patients with metastatic renal cell carcinoma (mRCC). Pembrolizumab, a PD-1 inhibitor, combined with epacadostat, an indoleamine 2,3-deoxygenase 1 selective inhibitor ...
Primo N. Lara   +19 more
doaj   +1 more source

Home - About - Disclaimer - Privacy